Phase 1 Trial Assessing PET Imaging Agent in Local and Advanced Prostate Cancers Enrolling Patients

Phase 1 Trial Assessing PET Imaging Agent in Local and Advanced Prostate Cancers Enrolling Patients
Cancer Targeted Technology (CTT) has initiated a Phase 1 clinical trial evaluating the safety and sensitivity of its positron emission tomography (PET) imaging agent, CTT1057, in detecting prostate cancer cells in patients with both localized and metastatic disease. The trial is supported by a $2 million Small Business Innovation Research (SBIR) grant, and imaged its first patients in early

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *